



Funding Friday Series - Episode 1



THE EIC ACCELERATOR WORK PROGRAMME 2026

- A PARADIGM SHIFT -

WHAT'S CHANGED AND WHY IT MATTERS FOR LIFE SCIENCES INNOVATIONS



Dr Caroline Chauché
Co-Managing Partner



The European Innovation Council (EIC) has fundamentally recalibrated its Accelerator programme for 2026, introducing changes that will reshape which life sciences companies successfully secure Europe's most prestigious innovation funding.

With €414 million allocated for open calls and a doubling of the minimum equity investment from €500,000 to €1 million, these modifications signal a strategic evolution toward later-stage companies with demonstrable commercial traction and co-investor interest.

For healthcare innovators, understanding these shifts isn't optional, it's essential for determining whether a company is positioned to compete effectively.



THE €1 MILLION EQUITY FLOOR: IMPLICATIONS FOR STARTUPS

Since its launch under Horizon Europe in 2021, the **EIC Accelerator** has supported 563 companies across diverse sectors, with life sciences dominating the funding landscape. Between 2021 and 2025, MedTech and Healthcare companies secured 35% of all awards (197 companies), while Biopharma captured 8.5% (48 companies). These numbers reveal evaluators' recognition that healthcare innovation inherently addresses the programme's core objectives: **breakthrough technologies solving critical societal challenges with clear European competitive advantage.**

In 2026, The doubling of minimum equity investment fundamentally transforms the EIC's risk-return profile. This **threshold signals** that the programme expects companies to demonstrate sufficient **maturity** that professional investors—venture capital firms, corporate venture arms, or sophisticated family office

are willing to co-invest at meaningful scale. For life sciences startups, this creates specific implications across different sectors. **Medical device** companies can typically achieve the required validation milestones within **12-18 months** using **€500K-€1M** in seed funding. Biotech companies, however, face fundamentally different capital requirements. Demonstrating **TRL 6** for therapeutics requires validation in

relevant biological systems, typically animal models that recapitulate human disease, demanding specialised facilities, regulatory compliance for animal work, and multi-month timelines.

The cost floor for meaningful **preclinical validation** frequently exceeds **€1-2 million**, creating the need of EIC funding to achieve TRL 8, but need to have completed TRL 5 to access EIC funding.

EIC Accelerator Success Stories [2021–2025]

- **Ebenbuild GMBH (Germany)** - Digital twin platform for respiratory health and personalized lung simulation for drug delivery (Twinhale). EIC Award (2025): €2.3M grant + €10M equity. Pilot studies with pharmaceutical partners (PARI Pharma, Pieris Pharmaceuticals), backed by VCs (HTGF, Bayern Kapital) prior to EIC award. Positioned to enter €300B+ clinical decision support personalized medicine markets. ebenbuild.com
- **Powerful Medical (Slovakia)** - AI-powered ECG interpretation doubling heart attack detection sensitivity. EIC Award (2024): €2.5M grant + €5M equity. Follow-on: €40M+ IPCEI Tech4Cure grant (2025), partnership with Roche, FDA Breakthrough Designation. 35K+ healthcare professionals, 400K patients screened. powerfulmedical.com
- **Better Medicine (Estonia)** - AI-powered cancer metastasis detection from CT scans. EIC Award (March 2023): €2.5M grant. Partnerships with Tartu University Hospital and Pärnu Hospital for clinical validation. SaaS-based AI models for kidneys, lungs, liver, pancreas metastasis detection. bettermedicine.ai
- **CattleEye (UK)** - AI-powered livestock monitoring for animal welfare and emissions reduction. EIC Award (March 2022): €2.5M grant. Exit: Acquired by GEA Group in March 2024 (2 years post-EIC funding). Monitors 100K+ cows worldwide, addresses 48% of EU agricultural emissions. cattleeye.com
- **Orixha (France)** - LuncoLive liquid ventilation for post-cardiac arrest syndrome. EIC Award (2022): €2.5M grant + €5M equity. Vent2Cool solution validated in physiological models. EIT Health Catapult finalist (2021), exploring additional critical care applications. orixha.com

Key Achievements: FDA designations, Big Pharma partnerships, VC backed prior to EIC award

Success Pattern: EIC validation → Follow-on funding (2-3x) → Strategic partnerships/exits within 2-3 years

Last Updated: November 2025 - Sources: EIC official announcements, company websites, press releases

THE MANDATORY TRL 5 THRESHOLD



The 2026 Work Programme's mandatory **achieved TRL 5** requirement creates asymmetric challenges across life sciences sectors. Unlike digital technologies that can iterate rapidly in software, life sciences innovations must demonstrate validation in relevant biological or clinical systems—a significantly higher bar requiring substantial preliminary data.

For medical devices, TRL 5 means technology validated in relevant environment—prototype devices tested in simulated use conditions, cadaver studies, or benchtop validation against clinical samples. While expensive, these activities can be completed within 12-18 months. **For diagnostics**, TRL 5 requires rigorous analytical validation and preliminary clinical verification, typically needing 100+ patient samples across multiple sites—creating substantial capital requirements many early-stage companies struggle to meet without major grant funding or investor capital.



TECHNICAL DUE DILIGENCE:

A NEW SCRUTINY LAYER

Perhaps the most consequential 2026 change is the introduction of technical **due diligence** by qualified experts before evaluation panels review proposals. Previously, while panels included domain experts, assessments relied on submitted documentation without independent technical verification. The new process means specialised experts will scrutinise **scientific claims**, **validation data quality**, **competitive positioning accuracy**, and **regulatory strategy feasibility** before applications reach the interview stage. For healthcare startups, this demands absolute **authenticity**.

Overstated claims about **technology performance** will be identified immediately. Incomplete validation data triggers **rejection** before reaching interviews. Regulatory strategies demonstrating naïveté about **EMA requirements** or clinical development pathways eliminate otherwise promising applications. Successful companies must present **validation data** with the same rigour expected in regulatory submissions or **investor due diligence**—comprehensive documentation of analytical performance, detailed protocols for clinical or field studies, and frank acknowledgment of remaining **technical challenges** with credible mitigation strategies.



STRATEGIC POSITIONING FOR 2026

Understanding these changes enables **strategic positioning**. First, assess your current TRL honestly using external validation rather than aspirational self-assessment. If genuinely at **TRL 4-5**, focus on accessing **Eurostars**, national innovation programmes, or **EIC Pathfinder/Transition** to reach TRL 6 before applying to the Accelerator. Second, begin cultivating co-investor relationships early—the €1 million minimum equity requirement means successful applications increasingly require confirmed **investment interest** through signed term sheets, letters of intent, or active syndication discussions. Third, prepare for technical **due diligence** by documenting everything with **regulatory-grade rigour**.

The 2026 EIC Accelerator represents Europe's most substantial non-dilutive funding opportunity for life sciences innovation. Success requires understanding how the programme has evolved and positioning your company accordingly—transforming the difference between **competing effectively** and investing six months in an application destined for **rejection**.

CONCLUSION: COMPETE & CONQUER



The EIC Accelerator Work Programme 2026 demands **strategic excellence**, raising the bar with a mandatory **TRL 6 threshold** and a doubled minimum equity investment to €1 million. While these changes increase the challenge, they simultaneously solidify the programme as Europe's most **substantial non-dilutive funding** opportunity for life sciences innovation. Successfully navigating this competitive landscape allows companies to secure not just critical funding, but also the **powerful EIC endorsement**, which is proven to **attract** up to 2-3x follow-on private **investment** and accelerate strategic partnerships and **exits** within 2-3 years. For innovators prepared to demonstrate regulatory-grade rigour and confirmed co-investor interest, competing for the EIC Accelerator is the definitive pathway to **conquer the market** and unlock future growth.

Author:

Dr Caroline Chauché, DVM, MSc, PhD
Co-Managing Partner
Strategic Healthcare Advisors

With support from Eric Del Cotto, MBA;
Dr Jean-Michel Verjus, PharmD and Dr
Francis Mathé, PharmD.

The 28th of November 2025, in Paris.



Driving Excellence
in Health Strategy

Our team understands what EIC evaluators and investors seek.

Contact us to discuss your EIC Accelerator strategy: contact@strategic-healthcare.eu

